Palabras clave
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

12604 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

PSS-10

- 7/1/24 - 1 formulario, 1 itemgroup, 10 items, 12 idiomas
Itemgroup: PSS-10
https://www.cmu.edu/dietrich/psychology/stress-immunity-disease-lab/scales/index.html Cohen S, Kamarck T, Mermelstein R: A global measure of perceived stress. J Health Human Behav 1983, 24:385-396. ; Cohen, S., & Williamson, G. (1988). Perceived stress in a probability sample of the U.S. In S. Spacapam & S. Oskamp (Eds.), The social psychology of health: Claremont Symposium on Applied Social Psychology. Newbury Park, CA: Sage. (provides NORMATIVE DATA for the PSS-4, PSS-10, and PSS-14 from a large U.S. sample polled in 1983) ; Cole, S. R. (1999). Assessment of differential item functioning in the Perceived Stress Scale-10. Journal of Epidemiology and Community Health, 53(5), 319. ; Roberti, J. W., Harrington, L. N., & Storch, E. A. (2006). Further psychometric support for the 10‐item version of the perceived stress scale. Journal of College Counseling, 9(2), 135-147. German version: Permission granted by Prof. Dr. Büssing. For psychometric values of the German version, refer to: Klein EM, Brähler E, Dreier M, Reinecke L, Müller KW, Schmutzer G, Wölfling K, Beutel ME. The German version of the Perceived Stress Scale - psychometric characteristics in a representative German community sample. BMC Psychiatry. 2016 May 23;16:159. doi: 10.1186/s12888-016-0875-9. PMID: 27216151; PMCID: PMC4877813. Greek version: Permission granted by Dr. Marios Adonis. Arabic version: Translation by Drs. Siraj Wali, Roah Merdad, Rawan Nassif, and Dr. Leena Merdad. Permission granted by Dr. Roah Merdad. Danish version: Translation by Drs. Anders Joergensen, Robert Zachariae, Lis Raabaek Olsen, Anita Eskildsen, Kent Nielsen, David Christiansen and Johan Hviid Andersen. Permission granted by Dr. Eskildsen. Hungarian version: Stauder, A., & Konkolÿ Thege, B. (2006). Az Észlelt Stressz Kérdőív (PSS) magyar verziójának jellemzői [Characteristics of the Hungarian version of the Perceived Stress Scale (PSS)]. Mentálhigiéné és Pszichoszomatika, 7, 203-216. Permission granted by Dr. Konkolÿ Thege. Norwegian version: Translation by CheckWare AS, Norway. Portuguese version: Trigo, M., Canudo, N., Branco, F., & Silva, D. (2010). Estudo das propriedades psicométricas da Perceived Stress Scale (PSS) na população portuguesa. Psychologica, (53), 353-378. Permission granted by Dr. Trigo. Serbian version: Jovanović, V., & Gavrilov-Jerković, V. (2015). More than a (negative) feeling: Validity of the Perceived Stress Scale in Serbian clinical and non-clinical samples. Psihologija, 48(1), 5-18. Permission granted by Dr. Veljko Jovanović. Sinhala version: "Adaptation and validation of the Depression, Anxiety, and Stress Scale (DASS21) among Students of the University of Colombo." (2012). A.V.S. Rekha Aththidiye., M.Phil in Clinical Psychology, Faculty of graduate studies, University of Colombo. Dr.Chandrika Ismail, Clinical Psychologist. Permission granted by Rekha Aththidiye. (Currently not included). Chinese version: Social Environment and Biomarkers of Aging Study (SEBAS), conducted by the Bureau of Health Promotion, Department of Health, Taiwan and translated into Chinese (for Taiwan) by Dr. I-Fen Lin. Permission granted by Dr. Dana Glei. Finnish version: Permission granted by Dr. Jukka Putaala. Turkish version: Yerlikaya, E. E. & İnanç, B. (2007), Psychometric Properties of the Turkish Translation of the Perceived Stress Scale (PSS), 9th National Congress of Psychological Counseling and Guidance, 17-19 October, İzmir.

Treatment - 2400 - Pre-Transplant Essential Data (TED) - 2492857v5.0 - 2400 - Pre-Transplant Essential Data (TED)

- 17/9/21 - 1 formulario, 69 itemgroups, 315 items, 1 idioma
Itemgroups: CIBMTR Use Only, Center Identification, Recipient Identification: Part 1 of 2, Study ID Number, Recipient Identification: Part 2 of 2, Recipient Race, Disease Classification, Hematopoietic Stem Cell Transplant (HSCT) : Part 1 of 4, Cell Source, Hematopoietic Stem Cell Transplant (HSCT) : Part 2 of 4, Donor Information, Hematopoietic Stem Cell Transplant (HSCT) : Part 3 of 4, Ex Vivo Graft Manipulation Type, Hematopoietic Stem Cell Transplant (HSCT) : Part 4 of 4, Preparative Regimen - Part 1 / 7, Preparative Regimen - Part 2 / 7, Preparative Regimen - Part 3 / 7 (Anthracyclines), Preparative Regimen - Part 4 / 7 (Monoclonal Antibodies), Preparative Regimen - Part 5 / 7 (Radiolabeled MAb), Preparative Regimen - Part 6 / 7 (Intent of Preparative Regimen), Preparative Regimen - Part 7 / 7 (Reason for NST / RIC), Comorbid Conditions, Type of Comorbid Condition, GVHD Prophylaxis, Post-HSCT Disease Therapy Planned as of Day 0, Type of Additional Post-HSCT Therapy, Other Toxicity Modifying Regimen, Pre-Transplant Essential Data Disease Classification Sheet, Acute Myelogenous Leukemia (AML) or Acute Nonlymphocytic Leukemia (ANLL): Part 1 of 2, Type of Therapy Related AML, Acute Myelogenous Leukemia (AML) or Acute Nonlymphocytic Leukemia (ANLL): Part 2 of 2, Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML): Part 1 of 2, CML Prior HSCT Treatment, Chronic Myelogenous Leukemia (CML): Part 2 of 2, Myelodysplastic or Myeloproliferative Disease Classification, Myelodysplastic or Myeloproliferative Diseases: Part 1 of 2, Type of Therapy Related MDS / MPS, Myelodysplastic or Myeloproliferative Diseases: Part 2 of 2, Other Leukemias, Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Plasma Cell Disorders, Breast Cancer, Other Disease, Other Malignancies, Anemia/Hemoglobinopathy, Platelet Disorders, Histiocytic Disorders, Inherited Disorders of Metabolism/Osteopetrosis, Immune Deficiencies, Autoimmune Disorders, Systemic Sclerosis Involvement, Systemic Sclerosis Laboratory Procedures, Systemic Lupus Erythematosus (SLE) Involvement, Systemic Lupus Erythematosus (SLE) Laboratory Procedures, Sjogren Syndrome Involvement, Polymyositis / Dermatomyositis Involvement, Polymyositis / Dermatomyositis Laboratory Procedure, Antiphospholipid Syndrome Involvement, Antiphospholipid Syndrome Laboratory Procedures, Wegener Granulomatosis Involvement, Wegener Granulomatosis Laboratory Procedures, Polyarteritis Nodosa Involvement, Polyarteritis Nodosa Laboratory Procedures, Rheumatoid Arthritis Involvement, Psoriatic Arthritis / Psoriasis Involvement, Multiple Sclerosis (MS) Involvement
Pre-Transplant Essential Data (TED) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=609D5967-37B1-F25E-E040-BB89AD437F88

Treatment - 2400 Revision 1 - Pre-Transplant Essential Data (TED) ISO Date Format - 2892485v2.0 - 2400 Revision 1 - Pre-Transplant Essential Data (TED) ISO Date Format

- 17/9/21 - 1 formulario, 69 itemgroups, 315 items, 1 idioma
Itemgroups: CIBMTR Use Only, Center Identification, Recipient Identification: Part 1 of 2, Study ID Number, Recipient Identification: Part 2 of 2, Recipient Race, Disease Classification, Hematopoietic Stem Cell Transplant (HSCT) : Part 1 of 4, Cell Source, Hematopoietic Stem Cell Transplant (HSCT) : Part 2 of 4, Donor Information, Hematopoietic Stem Cell Transplant (HSCT) : Part 3 of 4, Ex Vivo Graft Manipulation Type, Hematopoietic Stem Cell Transplant (HSCT) : Part 4 of 4, Preparative Regimen - Part 1 / 7, Preparative Regimen - Part 2 / 7, Preparative Regimen - Part 3 / 7 (Anthracyclines), Preparative Regimen - Part 4 / 7 (Monoclonal Antibodies), Preparative Regimen - Part 5 / 7 (Radiolabeled MAb), Preparative Regimen - Part 6 / 7 (Intent of Preparative Regimen), Preparative Regimen - Part 7 / 7 (Reason for NST / RIC), Comorbid Conditions, Type of Comorbid Condition, GVHD Prophylaxis, Post-HSCT Disease Therapy Planned as of Day 0, Type of Additional Post-HSCT Therapy, Other Toxicity Modifying Regimen, Pre-Transplant Essential Data Disease Classification Sheet, Acute Myelogenous Leukemia (AML) or Acute Nonlymphocytic Leukemia (ANLL): Part 1 of 2, Type of Therapy Related AML, Acute Myelogenous Leukemia (AML) or Acute Nonlymphocytic Leukemia (ANLL): Part 2 of 2, Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML): Part 1 of 2, CML Prior HSCT Treatment, Chronic Myelogenous Leukemia (CML): Part 2 of 2, Myelodysplastic or Myeloproliferative Disease Classification, Myelodysplastic or Myeloproliferative Diseases: Part 1 of 2, Type of Therapy Related MDS / MPS, Myelodysplastic or Myeloproliferative Diseases: Part 2 of 2, Other Leukemias, Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Plasma Cell Disorders, Breast Cancer, Other Disease, Other Malignancies, Anemia/Hemoglobinopathy, Platelet Disorders, Histiocytic Disorders, Inherited Disorders of Metabolism/Osteopetrosis, Immune Deficiencies, Autoimmune Disorders, Systemic Sclerosis Involvement, Systemic Sclerosis Laboratory Procedures, Systemic Lupus Erythematosus (SLE) Involvement, Systemic Lupus Erythematosus (SLE) Laboratory Procedures, Sjogren Syndrome Involvement, Polymyositis / Dermatomyositis Involvement, Polymyositis / Dermatomyositis Laboratory Procedure, Antiphospholipid Syndrome Involvement, Antiphospholipid Syndrome Laboratory Procedures, Wegener Granulomatosis Involvement, Wegener Granulomatosis Laboratory Procedures, Polyarteritis Nodosa Involvement, Polyarteritis Nodosa Laboratory Procedures, Rheumatoid Arthritis Involvement, Psoriatic Arthritis / Psoriasis Involvement, Multiple Sclerosis (MS) Involvement
Revision 1 of form 2400 - Pre-Transplant Essential Data (TED) Uses The ISO Date Format Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8331F8AF-85A0-6ABF-E040-BB89AD437A3C

Treatment - 2400 Revision 2 - Pre-Transplant Essential Data (TED) - 3002012v2.0 - 2400 Revision 2 - Pre-Transplant Essential Data (TED)

- 17/9/21 - 1 formulario, 71 itemgroups, 316 items, 1 idioma
Itemgroups: CIBMTR Use Only, Center Identification, Recipient Identification: Part 1 of 2, Study ID Number, Recipient Identification: Part 2 of 2, Recipient Race, Disease Classification, Hematopoietic Stem Cell Transplant (HSCT) : Part 1 of 4, Cell Source, Autologous HSCT, Hematopoietic Stem Cell Transplant (HSCT) : Part 2 of 4, Donor Information, Hematopoietic Stem Cell Transplant (HSCT) : Part 3 of 4, Ex Vivo Graft Manipulation Type, Hematopoietic Stem Cell Transplant (HSCT) : Part 4 of 4, Preparative Regimen - Part 1 / 7, Preparative Regimen - Part 2 / 7, Preparative Regimen - Part 3 / 7 (Anthracyclines), Preparative Regimen - Part 4 / 7 (Monoclonal Antibodies), Preparative Regimen - Part 5 / 7 (Radiolabeled MAb), Preparative Regimen - Part 6 / 7 (Intent of Preparative Regimen), Preparative Regimen - Part 7 / 7 (Reason for NST / RIC), Comorbid Conditions, Type of Comorbid Condition, GVHD Prophylaxis, Post-HSCT Disease Therapy Planned as of Day 0, Type of Additional Post-HSCT Therapy, Other Toxicity Modifying Regimen, Pre-Transplant Essential Data Disease Classification Sheet, Acute Myelogenous Leukemia (AML) or Acute Nonlymphocytic Leukemia (ANLL): Part 1 of 2, Type of Therapy Related AML, Acute Myelogenous Leukemia (AML) or Acute Nonlymphocytic Leukemia (ANLL): Part 2 of 2, Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML): Part 1 of 2, CML Prior HSCT Treatment, Chronic Myelogenous Leukemia (CML): Part 2 of 2, Myelodysplastic or Myeloproliferative Disease Classification at Diagnosis, Myelodysplastic or Myeloproliferative Disease Status at Transplantation, Myelodysplastic or Myeloproliferative Diseases: Part 1 of 2, Type of Therapy Related MDS / MPS, Myelodysplastic or Myeloproliferative Diseases: Part 2 of 2, Other Leukemias, Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Plasma Cell Disorders, Breast Cancer, Other Disease, Other Malignancies, Anemia/Hemoglobinopathy, Platelet Disorders, Histiocytic Disorders, Inherited Disorders of Metabolism/Osteopetrosis, Immune Deficiencies, Autoimmune Disorders, Systemic Sclerosis Involvement, Systemic Sclerosis Laboratory Procedures, Systemic Lupus Erythematosus (SLE) Involvement, Systemic Lupus Erythematosus (SLE) Laboratory Procedures, Sjogren Syndrome Involvement, Polymyositis / Dermatomyositis Involvement, Polymyositis / Dermatomyositis Laboratory Procedure, Antiphospholipid Syndrome Involvement, Antiphospholipid Syndrome Laboratory Procedures, Wegener Granulomatosis Involvement, Wegener Granulomatosis Laboratory Procedures, Polyarteritis Nodosa Involvement, Polyarteritis Nodosa Laboratory Procedures, Rheumatoid Arthritis Involvement, Psoriatic Arthritis / Psoriasis Involvement, Multiple Sclerosis (MS) Involvement
Revision 2 of form 2400 - Pre-Transplant Essential Data (TED) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=83325950-9451-ACDB-E040-BB89AD4322D7

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial